Pfizer : Biotech Finances

CETTE INFORMATION VOUS INTERESSE ?

Lettre Biotech Finances

www.biotech-finances.com
est élu source d'information à forte valeur ajoutée pour l'industrie

Abonnez-vous en ligne

Abonnement 1 an 44 numéros :

Premium classique : 1170€

Compte personalisé rechargeable :

Compte liberté (10€ minimum)

Pour entrer en contact avec nous, vous pouvez aussi nous joindre par téléphone au +33.(0)478 24 35 20

Pfizer

Pour accéder à la fiche complète (adresse , téléphone , email), veuillez vous connecter...

Activité :

Good health is vital to all of us, and finding sustainable solutions to the health care challenges of our changing world cannot wait. That's why we at Pfizer are committed to being a global leader in health care and to helping change millions of lives for the better through providing access to safe, effective and affordable medicines and related health care services to the people who need them. We have a leading portfolio of medicines that prevent, treat and cure diseases across a broad range of therapeutic areas, and an industry-leading pipeline of promising new products in areas such as oncology, cardiovascular disease and diabetes.To ensure that we deliver the value our patients and customers need and our shareholders deserve, we are focused on continually improving the way we do business; on operating with transparency in everything we do; and on listening to the views of all of the people involved in health care decisions. We know that we can best ensure that people everywhere have access to innovative medicines and quality health care through working in partnership with everyone from patients to health care providers, managed care organizations to world governments and non-governmental organizations

Site web : www.pfizer.fr

Réseau de l'entreprise

Broker

Computershare Trust Company --> Voir l'article

Prestataire en tant que

Membre

EBE --> Voir l'article

Réseau privé

Biosystems International --> Voir l'article

Partenaire industriel

Dedan Doogan, Directeur du développement international

Jeffrey Kindley, Directeur exécutif / CEO

Vidéos : 0 résultat

Articles : 69 résultats (page 1 sur 7)

15/03/2010 - Les raisins de la colère de GSK

Le torchon brûle entre GSK et l’une de ses dernières foucades, Sirtris Pharmaceuticals. En effet, l’an dernier, pour un peu plus de 720 millions de dollars,... (n°454, Le Billet Bio de H. ELLA, page 2)

15/03/2010 - Ablynx veut la valeur et l’argent de la valeur

La biotech belge Ablynx entame un revirement stratégique pour ses contrats de licences. Elle entend d’une part repousser ses partenariats à des stades plus avancés,... (n°454, Marchés, page 5)

01/03/2010 - ReNeuron enfin aux portes de la phase I

Les bonnes nouvelles s’enchaînent pour la biotech britannique ReNeuron Group (LSE : RENE.L). Après plusieurs mois d’échanges intenses... (n°452, Financement, page 5)

15/02/2010 - Italie : NexThera deale outre-Atlantique

Après plusieurs années de rachats, séparations et fusions successives, NexThera Biosciences franchit aujourd’hui un cap primordial, en signant un... (n°450, Partenariats, page 4)

12/02/2010 - Coup double pour Merus

L’année démarre en fanfare pour la biotech néerlandaise Merus, qui conclut deux belles opérations financières en parallèle. La première est le bouclage... (n°450, Financement, page 6)

02/11/2009 - Un nouveau cercle vertueux ou juste au milieu du gué

(n°437, Le Billet Bio de H. ELLA, page 1)

02/11/2009 - « La pharma doit se réinventer pour performer »

Prise dans l'étau des revenus en berne et d'une innovation au point mort, la pharma cherche çà et là des relais... (n°437, Interview, page 6)

23/10/2009 - Theralpha prend la douleur d'assaut

Selon le National Institutes of Health, plus de 40 millions d'Américains seraient aujourd'hui dans... (n°436, Entreprises, page 3)

12/10/2009 - À nouvelle politique, nouvelle renaissance

(n°434, Le Billet Bio de H. ELLA, page 2)

20/07/2009 - « L'environnement économique complexe est une opportunité pour faire de meilleurs deals »

Antoine Papiernik est partenaire-associé chez Sofinnova Partners, un capital-risqueur français qui a réalisé l'une des... (n°427, Interview, page 6)

Plus de résultats

Communiqués : 83 résultats (page 1 sur 9)

23/07/2008 Pfizer Reports Second-Quarter 2008 Results

... Pfizer Inc (NYSE: PFE): -0- *T ($ in millions, except per share amounts) Second-Quarter Year-to-Date ...

14/07/2008 Pfizer to Showcase Alzheimer's Research and Pipeline at Upcoming Alzheimer's Disease Medical Meeting

... Pfizer, Inc announced today that it will present nine abstracts from its Alzheimer's disease (AD) research and development program, including three on the two p ...

07/07/2008 Patients More Likely to Stay on Lipitor Than Simvastatin, a Large Observational Study Shows

... Pfizer announced today that new statin users who took Lipitor(R) (atorvastatin calcium) were significantly more likely to stay on their medication compared to t ...

12/06/2008 Pfizer Inc. and the University of Pennsylvania Announce $15 Million Partnership

... Pfizer Inc. (NYSE:PFE) announced today that it has entered into a $15-million dollar collaboration with the University of Pennsylvania School of Medicine. The p ...

10/06/2008 Pfizer Completes Acquisition of Encysive Pharmaceuticals Inc.

... Pfizer Inc (NYSE:PFE) today announced that it has completed the acquisition of all remaining outstanding shares of common stock of Encysive Pharmaceuticals Inc. ...

10/06/2008 Bristol-Myers Squibb and Pfizer Initiate New Study in the Apixaban Phase 3 Clinical Trial Program

... Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced today the start of a new Phase 3 clinical trial to assess the effect of apixaban in pa ...

05/06/2008 Charles E. Triano Joins Pfizer as Head of Investor Relations

... Pfizer Inc today announced that Charles E. Triano will join the company as Senior Vice President, Investor Relations, effective June 23. Mr. Triano, who will be ...

04/06/2008 Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

... Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Martin Mackay, President, Pfizer Global Research & ...

02/06/2008 Updated CDX-110 Data in Glioblastoma Multiforme Presented at 44th Annual ASCO Annual Meeting

... AVANT Immunotherapeutics (Nasdaq: AVAN) and Pfizer, Inc. (NYSE: PFE) today announced the presentation of new data from two Phase 2 studies at the 44th Annual Me ...

02/06/2008 New Pfizer Data Presented on CP-751,871 across Non-Small Cell Lung Cancer and Ewing's Sarcoma

... Pfizer announced today results from several clinical trials further describing the activity of its investigational compound CP-751,871 in non-small cell lung ca ...